The VALOR Study – A Clinical Trial for People Living with SOD1-ALS

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) carrying a SOD1 gene mutation.

Update 31-12-2021: Please note that the study is now active and enrolment is completed.

Study Duration

• 32-36 weeks, including:
• 4-week screening
• 24-week study treatment period
• 4 to 8-week follow-up period

Investigational Drug

• Tofersen (BIIB067), an antisense oligonucleotide (ASO)
• Designed to reduce the amount of SOD1 protein in the body
• Given intrathecally, through a lumbar puncture

Key Eligibility Criteria

• 18 years of age or older
• Have weakness caused by ALS
• Agree to genetic testing for the SOD1 mutation

All Eligible Participants Will Receive At No Cost

• Comprehensive study-related health evaluations and assessments, including genetic testing
• Investigational drug or placebo
• All study-related visits and care

Assistance with travel and accommodations, and reimbursement for study-related expenses may also be available. See if you may be eligible and view our study locations.